论文部分内容阅读
近年来新蝶呤作为细胞间免疫活动的标志已引起人们重视。本文作者采用放免法测定146例肝病患者和120例健康人血、尿新蝶呤含量,试图发现新蝶呤与肝脏疾病和肝功能试验之间的关系。肝病患者146例。其中16例HBSAg 健康携带者(ASC),12例急性病毒性肝炎(AH),46例肝硬化(LC),13例慢性迁延性肝炎(CIH),35例慢性活动性肝炎(CAH),18例肝癌(HCC),6例酒精性肝病(ALD)。所有患者均排除肾脏疾病,未接受免疫抑制治疗和抗病毒治疗。患者体重、尿钠、氯及钾的排泄和肌酐处于稳定状态。健康组120例与肝病组无性别和年龄的差异。
In recent years, neopterin as a sign of intercellular immune activity has attracted people’s attention. The authors used radioimmunoassay to determine the blood and urine neopterin levels in 146 patients with liver disease and 120 healthy subjects and tried to find out the relationship between neopterin and liver disease and liver function tests. 146 cases of liver disease. Among them, 16 were HBSAg carriers (ASC), 12 patients with acute viral hepatitis (AH), 46 patients with cirrhosis (LC), 13 patients with chronic persistent hepatitis (CIH), 35 patients with chronic active hepatitis (CAH), 18 Cases of liver cancer (HCC), 6 cases of alcoholic liver disease (ALD). All patients were excluded kidney disease, did not receive immunosuppressive therapy and antiviral therapy. Patients’ body weight, urinary sodium, chloride and potassium excretion and creatinine were in steady state. 120 cases of healthy group and liver disease group without gender and age differences.